IRI tracks healthcare trends
This article was originally published in The Tan Sheet
Executive Summary
Information Resources, Inc. will roll out a 34,000-plus consumer panel to track and measure consumer purchases of pharmaceuticals. RxPulse "will allow clients to monitor Rx and OTC drug usage across key segments, including ailments treated, consumer attributes and channel purchasing, for both conventional retail and online buying," IRI says June 14. Panel is first phase of what IRI terms a "suite of services for the pharmaceutical and health care markets." Market research firm also is conducting surveys to examine consumer purchase habits related to Rx, OTC drugs using InfoScan retail scanner data. IRI's announcement comes shortly after ACNielsen launched its Homescan Rx/OTC Consumer Panel, which will involve roughly 24,000 people (1"The Tan Sheet" June 3, 2002, p. 14)...
You may also be interested in...
Rx-To-OTC Consumer Purchase Trends To Be Tracked By ACNielsen
ACNielsen's U.S. Homescan Rx/OTC Consumer Panel will help the pharmaceutical industry monitor consumers' purchasing trends with regard to new switch drugs, the market research firm contends
Boehringer Ingelheim, Gubra Enter Third Obesity Deal
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: